ACRS Aclaris Therapeutics Inc.

1.73
-0.11  -6%
Previous Close 1.84
Open 1.79
Price To Book 0.84
Market Cap 71,601,987
Shares 41,388,432
Volume 538,951
Short Ratio
Av. Daily Volume 671,835
Stock charts supplied by TradingView

NewsSee all news

  1. Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

    •  Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6•  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa., Jan. 09, 2020

  2. Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors

    WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent

  3. Aclaris Therapeutics to Present at Upcoming Investor Conferences

    WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at

  4. Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

    Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development PipelineDivested RHOFADE® (oxymetazoline hydrochloride) cream, 1%Repaid $30 Million Term Loan Successful Pivotal Phase 3

  5. Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

    WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (ATI-50002-AA-201) - dose ranging
Alopecia areata
Development to be discontinued - noted August 8, 2019.
ATI-502 (VITI-201 Topical)
Vitiligo
Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Partner required to further development.
ATI-502
Androgenetic alopecia (AGA) - Hair loss
Phase 2 trial completed.
ATI-502 (AD-201 Topical)
Atopic dermatitis (AD)
Phase 2 trial to be initiated 1H 2020.
ATI-450
Rheumatoid arthritis (RA)

Latest News

  1. Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

    •  Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6•  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa., Jan. 09, 2020

  2. Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors

    WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent

  3. Aclaris Therapeutics to Present at Upcoming Investor Conferences

    WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at

  4. Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

    Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development PipelineDivested RHOFADE® (oxymetazoline hydrochloride) cream, 1%Repaid $30 Million Term Loan Successful Pivotal Phase 3

  5. Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

    WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results

  6. Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

    If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpointHighly statistically

  7. Aclaris Therapeutics Announces Divestiture of RHOFADE®

    WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE®

  8. Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%

    WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with

  9. Aclaris Therapeutics to Hold R&D Day

    WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day

  10. Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

    Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29Highly statistically significant results on all secondary efficacy endpointsWART-302 is the first of two

  11. NATIONALLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM – ACRS

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from May 8, 2018 through June 20, 2019,

  12. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS) of the September

  13. Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) filed a class action complaint against the company's officers and directors for

  14. Pomerantz Law Firm Announces the Filing of a Class Action against Aclaris Therapeutics Inc. and Certain Officers – ACRS

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS) and certain of its officers.

  15. Aclaris Therapeutics Announces New Strategic Direction

    Completion of Strategic Review and Refocusing of Resources on Immuno-Inflammatory Development PipelineActively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream, 1%Actively Exploring

  16. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS) of the September

  17. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE:MNK), Oasmia

  18. HIGHLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS

    NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from May 8, 2018 through June 20, 2019,

  19. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS) of the September

  20. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS). Such investors are advised to contact

  21. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - August 28, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ("Aclaris" or the "Company") of

  22. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Oasmia Pharmaceutical AB (NASDAQ:OASM), Aclaris

  23. ACRS: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from May 8, 2018

  24. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

    NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS). Such investors are advised to

  25. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

    NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ:ACRS). Such investors are advised to

  26. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In OASM, ACRS, GTT or JE To Contact The Firm

    New York, New York--(Newsfile Corp. - August 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm:Company: Oasmia